公开(公告)号：US20210323991A1

公开(公告)日：2021-10-21

申请号：US17251964

申请日：2019-06-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Richard A. Hartz ,  Li Xu ,  David S. Yoon ,  Alicia Regueiro-Ren ,  Prasada Rao Jalagam ,  Manoranjan Panda ,  Satheesh Kesavan Nair

IPC: C07H17/04 ,  A61P13/12

Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.

公开(公告)号：US20210147408A1

公开(公告)日：2021-05-20

申请号：US16650403

申请日：2018-09-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Prasada Rao Jalagam ,  Satheesh Kesavan Nair ,  Manoranjan Panda ,  Ramakanth SARABU ,  Jacob SWIDORSKI ,  Brett R. BENO ,  Alicia Regueiro-Ren

IPC: C07D417/14 ,  C07D405/14

Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US20200339550A1

公开(公告)日：2020-10-29

申请号：US16928079

申请日：2020-07-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20190127380A1

公开(公告)日：2019-05-02

申请号：US16094288

申请日：2017-04-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Prashantha Gunaga ,  Jeremy Richter ,  Navnath Dnyanoba Yadav ,  Manoranjan Panda ,  Sreenivasulu Godesi

IPC: C07D487/04 ,  C07D407/04 ,  C07D471/04 ,  C07D407/06 ,  C07D413/14 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CR4 or N; Y is CR4 or N, provided that Y is N only if X is N; R1 is Formulae (A) or (B); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, R3, R4, L1, R1a, R1b, R1c, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US11970511B2

公开(公告)日：2024-04-30

申请号：US17251964

申请日：2019-06-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Richard A. Hartz ,  Li Xu ,  David S. Yoon ,  Alicia Regueiro-Ren ,  Prasada Rao Jalagam ,  Manoranjan Panda ,  Satheesh Kesavan Nair

IPC: C07H17/04 ,  A61P13/12

CPC classification number: C07H17/04 ,  A61P13/12

Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.

公开(公告)号：USRE49700E1

公开(公告)日：2023-10-17

申请号：US17183286

申请日：2021-02-23

Applicant: Bristol-Myers Squibb Company

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

CPC classification number: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I)




or a salt thereof,

wherein R1 is:





each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20230167131A1

公开(公告)日：2023-06-01

申请号：US17799028

申请日：2021-02-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Kumaravel Selvakumar ,  Venkatram Paidi ,  Srinivasan Thangathirupathy ,  Vijaya Kumar Cm ,  Tirupathi Rao Alajangi ,  Mallikarjun Reddy Sura ,  Krishna Mahadevu ,  Ramesh Kumar Sistla ,  Piyush Agarwal ,  Arul Mozhi Subbiah Karuppiah ,  Jalathi S. Nair ,  Ooha Morampudi ,  Manoranjan Panda ,  Joseph A. Tino ,  Robert J. Cherney ,  John V. Duncia ,  Daniel S. Gardner ,  T. G. Murali Dhar ,  Audrey Graham Ross ,  Paul E. Gormisky ,  Xiao Zhu ,  Boris M. Seletsky ,  Alyssa H. Antropow ,  Deqiang Niu ,  Zhengdong Zhu ,  Guobin Miao ,  Julio Herman Cuervo

IPC: C07D519/00 ,  C07D471/04 ,  C07D487/04 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D519/00 ,  C07D471/04 ,  C07D487/04 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14

Abstract: The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.

公开(公告)号：US11072626B2

公开(公告)日：2021-07-27

申请号：US16754381

申请日：2018-10-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Prasada Rao Jalagam ,  Satheesh Kesavan Nair ,  Manoranjan Panda ,  Alicia Regueiro-Ren

IPC: C07H19/056 ,  C07H19/052 ,  C07H19/24

Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US11014922B2

公开(公告)日：2021-05-25

申请号：US16347849

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  Guohua Zhao ,  Susan Nicole Pieniazek ,  Kumaravel Selvakumar ,  Suresh Dhanusu ,  Manoranjan Panda ,  Lawrence R. Marcin

IPC: C07D471/04 ,  A61K31/4375 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US10829501B2

公开(公告)日：2020-11-10

申请号：US16739363

申请日：2020-01-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Leon M. Smith, II ,  Vladimir Ladziata ,  Indawati DeLucca ,  Donald J. P. Pinto ,  Michael J. Orwat ,  Andrew K. Dilger ,  Kumar Balashanmuga Pabbisetty ,  Wu Yang ,  Scott A. Shaw ,  Peter W. Glunz ,  Manoranjan Panda

IPC: C07D513/04 ,  C07D213/64 ,  C07D231/18 ,  C07D471/04 ,  C07D471/12 ,  C07D413/12 ,  C07D401/12 ,  C07D231/54 ,  C07D401/14 ,  C07D231/12 ,  A61P15/10 ,  A61P9/10 ,  C07D239/06

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.